Target intelligence / Profile preview

Emm55 protein, Streptococcus pyogenes (Emm55)

Target
Emm55
Molecular classification
Bacterial surface protein, Bacterial outer membrane protein
01

Overview

Emm55 protein is a variant of the M protein family from *Streptococcus pyogenes*, encoded by the emm55 gene. M proteins are key virulence factors that are anchored to the bacterial cell wall and function predominantly in immune evasion and, in some variants, in mediating interactions with extracellular matrix components like collagen[1]. The Emm55 protein is immunogenic and has been investigated as a bacterial antigen to stimulate immune responses against cancer. In preclinical studies, DNA vaccines encoding emm55 have shown the ability to enhance T cell infiltration and antitumor immune activity in murine models, especially when combined with immune checkpoint blockade therapies such as anti-PD-1 antibodies[2][3]. Emm55 is used primarily in the context of cancer immunotherapy, not as a classical drug target (e.g., receptor, enzyme), but as a therapeutic antigen for immune activation. There is no indication of misspelling or incorrectness in the usage of "Emm55-derived bacterial protein" for structured data extraction.

Other names
Emm55 bacterial proteinEmm55 (S. pyogenes)M protein variant 55
02

Mechanism of action

Acts as an immunogenic antigen that can stimulate tumor-infiltrating T cells and activate antigen-specific immune responses Enhances immune-mediated tumor cell killing in combination with immune checkpoint inhibition

03

Biological functions

Immune response activationAntigenicity stimulationInduction of antitumor immunity
04

Disease associations

Cancer (as a component in immunotherapy)Infection (Streptococcus pyogenes pathogenesis)
05

Safety considerations

General risks associated with immunotherapy, such as potential for immune-related adverse eventsSpecific safety risks not defined in references; further studies would be necessary
06

Interacting drugs

None directly known as conventional drugs; interacts functionally with anti-PD-1 antibody (when used in combination immunotherapy)
07

Biomarkers

Increase in CD8+ and antigen-specific T cell infiltration after Emm55-based immunotherapy

Beyond the preview

Go deeper on Emm55 protein, Streptococcus pyogenes (Emm55).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Emm55 protein, Streptococcus pyogenes (Emm55).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call